BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-10 out of 335 found
  Current Search:      

HTML
100%
SPOT ON media and LIVESTRONG(R) Launch LIVESTRONG Quarterly
NEW YORK, Feb.

9 /PRNewswire/ -- LIVESTRONG Quarterly is a new online, print and print-on-demand publication from LIVESTRONG.

The magazine features profiles of survivors and supporters in the fight against cancer; resources and information about cancer...

TickerTech.com:  Feb 9 2010 8:35PM Find similar documents
HTML
100%
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
10.5699 0.3699 3.63% Enter Symbols: Sponsored by: Conference Call and Webcast to Follow ROCKVILLE, Md., Feb.

9 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc.

(Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and...

TickerTech.com:  Feb 9 2010 8:32PM Find similar documents
HTML
100%
Reproductive Partners Announces The Success Prime IVF Program
Reproductive Partners Announces The LOS ANGELES, Feb.

9 /PRNewswire/ -- Reproductive Partners Medical Group, Inc.

announces the launch of the , an IVF money back guarantee for best-case patients.'The is really very simple,' says Dr.

Arthur Wisot of...

TickerTech.com:  Feb 9 2010 3:41PM Find similar documents
HTML
100%
Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
Related Quotes Chattem Incorporated 93.32 0.10 0.11% Sanofi Aventis 35.91 0.40 1.13% Enter Symbols: Sponsored by: //var ord = Math.random() * 10000000000000000; write('//var ord = Math.random() * 10000000000000000; write(' PARIS, Feb.

9 /PRNewswire-FirstCall/...

TickerTech.com:  Feb 9 2010 8:24AM Find similar documents
HTML
100%
Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
ABBOTT PARK, Ill., Feb.

8 /PRNewswire-FirstCall/ -- A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States.

Abbott's ARCHITECT HE4 assay uses a simple blood test to...

TickerTech.com:  Feb 9 2010 5:29AM Find similar documents
HTML
100%
Westaim announces completion of amalgamation with NUCRYST Pharmaceuticals Corp.
Related Quotes Westaim Corporation 0.59 UNCH 0.0% Westaim Corporation 0.59 UNCH 0.0% Enter Symbols: Sponsored by: //var ord = Math.random() * 10000000000000000; write('//var ord = Math.random() * 10000000000000000; write(' TORONTO, Feb.

8 /CNW/ - The Westaim...

TickerTech.com:  Feb 9 2010 2:25AM Find similar documents
HTML
100%
Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
Style Definitions span.prnews_span span.prnews_wider a.prnews_a li.prnews_li p.prnews_p ST.

LOUIS, Feb.

8 /PRNewswire-FirstCall/ -- Cost reductions offset a recession-driven sales decline to move Allied Healthcare Products (Nasdaq: ) narrowly into...

TickerTech.com:  Feb 9 2010 1:55AM Find similar documents
HTML
100%
US FDA Approves New Indication for CRESTOR(R) (rosuvastatin calcium)
WILMINGTON, Del., Feb.

8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and...

TickerTech.com:  Feb 9 2010 1:55AM Find similar documents
HTML
100%
RegenceRx Leads the Industry With Introduction of Medication Cost Integration
PORTLAND, Ore., Feb.

8 /PRNewswire/ -- Rapid developments in the pharmaceutical industry have led to a steady increase in the use and cost of 'specialty' medications to treat chronic conditions such as arthritis and psoriasis.

This has led to some...

TickerTech.com:  Feb 9 2010 1:55AM Find similar documents
HTML
100%
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Pat
THOUSAND OAKS, Calif., Feb.

8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced...

TickerTech.com:  Feb 9 2010 1:55AM Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.